Published 24 hours ago • loading... • Updated 24 hours ago

Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)

On Wednesday, May 20, 2026, the National Medical Products Administration approved Mabwell's MAIWEIJIAN for treating bone metastases from solid tumors and multiple myeloma.
MAIWEIJIAN binds to RANKL to block the RANKL/RANK/OPG pathway, preventing skeletal complications more effectively than bisphosphonates commonly used in clinical practice.
Mabwell previously published Phase I and Phase III clinical research findings for the Denosumab Injection in International Immunopharmacology and JAMA Oncology, systematically verifying safety and efficacy.
Expanding its global footprint, Mabwell signed formal cooperation agreements for MAIWEIJIAN with 33 countries, while registration applications have been submitted to 8 additional nations including Jordan, Egypt, and Brazil.
The company remains committed to its mission to "Explore Life, Benefit Health" as it advances therapies for oncology and aging-related diseases through its integrated industry chain.

Insights by Ground AI

41 Articles

Bennington Banner

+40 Reposted by 40 other sources

Center

Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)

SHANGHAI, May 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application for MAIWEIJIAN (Denosumab Injection, R&D code: 9MW0321), which was independently developed by its wholly-owned subsidiary T-mab,…

24 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year